Murine fibroblasts expressing viral receptors and human cyclin T1 allow HIV-1 entry and viral gene expression but do not support efficient assembly. A chimeric HIV-1 carrying a non-homologous matrix (MA) from murine leukemia virus in place of HIV-1 MA can assemble efficiently in murine cells, yet has poor infectivity. Here, we assess the ability of a homologous MA from SIV MAC239 to complement assembly and infection in chimeric viruses designated SHIV(MA). The resulting SHIV(MA) chimeras produce more virus than native HIV-1 when transfected into murine cells. SHIV(MA) exhibits cell-type-specific replication in human T cell lines, replicating well in MT4 cells and poorly in Jurkat cells due to an incompatibility with the HIV-1 Env. The infectivity defects of SHIV(MA) are rescued by pseudotyping with VSV-G but not by truncation of the cytoplasmic tail of Env. Passage of SHIV(MA) in Jurkat cells produces variants with improved Env incorporation and improved replication in Jurkat but not in 3T3 TXC cells. The results indicate that cell-type-specific, or species-specific, host factors interact with MA to modulate the efficiency of assembly and its compatibility with Env. With additional selection, SIV/HIV-1 chimeras may be useful for the development of murine models of lentiviral infection.
Introduction
The MA domain of Gag is responsible for targeting HIV-1 assembly to specific membrane compartments in the cell (Facke et al., 1993; Freed et al., 1994) . In addition, it plays a key role in recruiting Env to make infectious virus particles. In murine fibroblasts, the targeting of Gag to the plasma membrane is inefficient, resulting in poor virus production (Bieniasz and Cullen, 2000; Garber et al., 1998; Mariani et al., 2000) . In murine cells, the p55 Gag precursor accumulates in an unprocessed form and fails to associate efficiently with the plasma membrane (Bieniasz and Cullen, 2000; Koito et al., 2003; Reed et al., 2002; Swanson et al., 2004) .
MA plays an important role in this murine cell phenotype. The membrane binding activity of MA is thought to be regulated during viral assembly by a myristoyl switch mechanism (Paillart and Gottlinger, 1999; Spearman et al., 1997; Tang et al., 2004) . The poor association of Gag with the plasma membrane in murine cells suggests that the activation of the membrane binding activity of the MA domain fails to occur in these cells (Koito et al., 2003; Swanson et al., 2004) . We and others have found that replacement of the HIV-1 MA domain with the murine leukemia virus (MuLV) MA domain in a full-length proviral clone of HIV-1 significantly enhances the ability of Gag to localize into punctate structures at the plasma membrane and to assemble into virus particles (Chen et al., 2001; Reed et al., 2002) . These experiments demonstrate that changing the MA domain with a functional homologue from a distantly related virus can enhance the efficiency of viral assembly in a cell-type-dependent manner. The ability of these MHIV(MA) chimeras to replicate in human cells was limited in part by poor incorporation of HIV-1 Env into virus. MHIV(MA) chimeras require a deletion of the Env cytoplasmic tail to exhibit low-level infectivity and replicated weakly only in MT4 cells after prolonged culture (Chen et al., 2001; Reed et al., 2002) . Thus, the MLV MA complements assembly functions of HIV-1 MA but poorly complements other MA functions.
It is still unclear what host factors are responsible for the inability of HIV-1 to assemble in murine cells. Experiments with human-murine heterokaryons suggest that the poor efficiency of assembly in murine cells is due to the absence of a species-specific cofactor(s) (Bieniasz and Cullen, 2000; Mariani et al., 2001) . Other experiments focusing on the efficiency of splicing in murine cells have found that the human splicing regulatory protein, p32, can enhance assembly by increasing Gag production in murine cells (Zheng et al., 2003) . Another report indicates that the RNA export pathway of the Gag-encoding RNA influences the efficiency of HIV-1 assembly in murine cells, in a manner that is independent of Gag expression levels (Swanson et al., 2004) .
Host restriction of viral infection is frequently determined by very minor sequence differences in viral or host proteins. For example, a single amino acid substitution in the murine cyclin T1 protein is sufficient to change the inactive mouse protein into an efficient HIV-1 Tat cofactor (Garber et al., 1998) . Single amino acid differences in the antiviral APOBEC3G protein are responsible for the inability of HIV-1 Vif to inactivate the simian version of the gene (Bogerd et al., 2004; Mangeat et al., 2004; Schrofelbauer et al., 2004) . Minor sequence differences in the CA domain of Gag are responsible for the poor ability of HIV-1 to infect old world monkey cells (Hatziioannou et al., 2004; Ikeda et al., 2004) . While the SIV MA domain is highly related to HIV-1 MA, some reports suggest that the SIV MA domain may have a greater ability to support assembly independently from the rest of Gag (Giddings et al., 1998; Gonzalez et al., 1993) . Therefore, we were interested in determining whether the MA domain from SIV MAC239 can complement assembly functions in human or murine cells in the context of HIV-1 chimeras. The extent to which the SIV MA complements HIV-1 MA functions provides insights into the interactions of MA with both viral and host factors.
In this report, we examined chimeric HIV-1 molecular clones carrying SIV MAC 239 MA in place of HIV-1 MA. When pseudotyped in murine cells, SHIV(MA) was able to produce greater levels of virus. Furthermore, these SHIV(MA) chimeras replicated in a cell-type-specific manner in human T cells and could be adapted to replicate efficiently in Jurkat T cells, yet they did not replicate in multiple rounds in murine fibroblasts. Replacement of the sequences of HIV-1 MA with SIV MA has cell-type-specific effects upon both assembly and Env incorporation.
Results

SHIV(MA) chimeric virus strategy, sequence conservation, and structural alignment
The amino acid sequences of HIV-1 and SIV MA are homologous and are believed to assume similar structures (Hill et al., 1996; Massiah et al., 1994; Matthews et al., 1994; Rao et al., 1995) . Sequence comparisons at the amino acid level show that the first 96 amino acids are well conserved with SIV MAC 239 MA and HIV(NL4-3) MA sharing 58% identity ( Fig. 1A) .
Structures of both protein domains can be readily aligned. A ribbon diagram of the aligned alpha carbon backbones shows that they fold into very similar structures ( Fig. 1B) (Hill et al., 1996; Rao et al., 1995) . The C-terminal 30 amino acids of HIV- Fig. 1 . Replacement of the MA domain of HIV-1 with the well-conserved SIV MA sequence. (A) Primary sequence alignment of SIV and HIV-1 MA domains shows high sequence conservation. Identical residues are boxed in yellow. Secondary structure is indicated by helical domains H1 through H5 in HIV-1 and SIV MA. The beta turn sequence in SIV is also indicated. (B) Ribbon diagram representing a structural alignment of alpha carbon backbone of SIV and HIV-1 MA domains reveals a high structural similarity. Superimposition of SIV MA (Rao et al., 1995) and HIV-1 MA (Tang et al., 2002) structures was produced using the UCSF Chimera package from the Computer Graphics Laboratory, University of California, San Francisco (Pettersen et al., 2004) . (C) Schematic illustration of the design of two HIV-1 MA-chimeric viruses, SHIV(MA) and SHIV(MA N1-96), which respectively replace all or only the most conserved sequences of HIV-1 MA with sequences from SIV MAC 239 MA. Design of second generation MLV MA chimeras MHIV(MA)v2 and MHIV(MA12)v2 are similar to those previously published (Chen et al., 2001) with the insertion of a native HIV MA-CA cleavage site (indicated by the sequence SQNY^PIVQ) at the boundary of the MLV MA and the HIV CA in MHIV(MA)v2, or between MA and p12 in MHIV(MA12)v2.
1 and SIV MA are not conserved. In HIV-1, this region forms an extended helix, whereas in SIV, this region forms a beta turn. Studies on the isolated SIV MA domain suggest that despite this high similarity to HIV-1 MA, it differs from HIV-1 MA in its ability to assemble autonomously into virus like particles (Giddings et al., 1998; Gonzalez et al., 1993) . We were therefore interested in understanding how well the SIV MA domain would function in place of HIV-1 MA in full-length proviral constructs.
Two SHIV(MA) chimeric viruses were created to test the ability of the MA from SIV MAC239 to enhance assembly in murine cells and to examine its compatibility within an HIV-1 genome (Fig. 1C ). The first construct, SHIV(MA), carried the full SIV MA domain in place of the HIV-1 MA domain. A second chimera, SHIV(MA N1-96), replaced only the conserved N-terminal 96 amino acids of SIV MA in place of a similar portion of HIV-1 MA while maintaining the native HIV-1 MA C-terminus. Because the presence of the cytoplasmic tail of Env can interfere with Env incorporation in MA chimeras (Chen et al., 2001; Reed et al., 2002) , we also created variants of these constructs with a deletion of the last 144 amino acids of the Env cytoplasmic tail.
SIV MA complements HIV-1 assembly functions in human cells
Transfection of SHIV(MA) chimeras into human 293T cells showed that both SHIV(MA) and SHIV(MA N1-96) produced a p55 precursor of a similar size to native HIV-1 p55 ( Fig. 2A , lanes 2 and 3). Proteolytic processing of both SHIV(MA) Gags associated with the cell lysates also appeared similar to native Gag. To compare the expression and processing of SHIV(MA) chimeras with other MA chimeras, we tested the chimeras MHIV(MA)v2 and MHIV(MA12)v2 (Fig. 1C) , which carry the MLV MA domain or the MLV MA and p12 domains in place of HIV-1 MA (Chen et al., 2001) . Both MLV MA chimeric Gag proteins were also expressed well, with Gag precursor and p24 evident in the Western analysis of transfected 293T cell lysates ( Fig. 2A , lanes 4 and 5).
Western blot analysis of the sucrose-pelleted viral supernatants from transfected 293T cells shows that both SHIV(MA) constructs produced virus particles with a similar efficiency to native HIV-1 and both MHIV(MA) chimeras ( Fig. 2B ). Quantitative p24 ELISA of the sucrose-pelleted supernatants shows that the SHIV(MA) and SHIV(MA N1-96) chimeras produced particles within two-fold of native HIV-1 and both MHIV(MA) chimeras in 293T cells (Fig. 2C ).
SIV MA enhances assembly of HIV-1 in murine cells
In transfected murine 3T3 TXC cells (Chen et al., 2001) , which stably express the human genes for CD4, CXCR4, and CyclinT1, the SHIV(MA) and SHIV(MA N1-96) Gag precursors were both produced at a level similar to native HIV-1 (Fig. 3A ). Native HIV-1, SHIV(MA), and SHIV(MA N1-96) all showed a dominant p55 precursor band. A faint p24 band is present in the SHIV(MA) and SHIV(MA N1-96) lanes that is not observed in the HIV-1 lane. In comparison, constructs carrying murine leukemia virus MA, MHIV(MA)v2, or both MLV MA and p12, MHIV(MA12)v2, expressed lower levels of steady-state Gag precursor in the cells and also gave rise to a p24 band (Fig. 3A, lanes 4 and 5) . In these lanes, the MHIV chimeras had a lower levels of precursor Gag associated with the cell lysates as compared to HIV-1 or either SHIV(MA) chimera.
Western blot of the sucrose-pelleted virus particles showed that both the SHIV(MA) and SHIV(MA N1-96) viruses produced more p24 than native HIV-1 in murine cells (Fig.  3B , lanes 8 and 9), whereas little virus was released from the cells transfected with native HIV-1. As a basis for comparison, MHIV(MA)v2 and MHIV(MA12)v2 produced higher levels of p24 than native HIV-1 as well ( Fig. 3B , lanes 10 and 11). When measured by quantitative p24 ELISA, 3T3 TXC cells transfected with SHIV(MA) and SHIV(MA N1-96) each released 20-to 30fold more virus than native HIV-1 (Fig. 3C ). The MHIV(MA) and MHIV(MA12) constructs released 60-fold more p24 than native HIV-1 (Fig. 3C ). The magnitude of the improvement in virus particle production by both SHIV(MA) chimeras was comparable to that observed from the MLV MA-carrying chimeras, MHIV(MA)v2 and MHIV(MA12)v2.
To examine the fraction of sucrose pelleted p24 antigen released from cells relative to that retained in the cell at steady state, we divided the cell-associated p24 levels by the virusassociated p24 levels to come up with a relative antigen retention to release (ARR) ratio ( Table 1 ). The ARR ratios for all five constructs in 293T cells were all fairly close to 0.6, whereas the ARR ratios were markedly different between viral constructs in the 3T3 TXC cells. HIV-1 antigen was highly retained in the 3T3 TXC cells with an ARR ratio of 17.71, whereas the SHIV(MA) and SHIV(MA N1-96) chimeras had ratios of 0.57 and 0.54. MHIV(MA)v2 and MHIV(MA12)v2 retained even less antigen (Fig. 3A , lanes 4 and 5; Fig. 3C ), and as a result had very low ARR ratios of 0.09 and 0.10 respectively.
SHIV(MA) and SHIV(MA N1-96) replicate in MT4 cells but not in Jurkat cells
Previous studies with MLV MA chimeras have found the viruses to be attenuated in their ability to replicate in human T cell lines. To examine the ability of SHIV(MA) chimeras to replicate in T cell lines, we produced viruses by transient transfection of 293T cells. Supernatants containing 15 ng of p24 CA antigen from each virus were used to infect transformed CD4 + T cell lines, MT4, or Jurkat. MT4 cells have been shown to support the replication of viruses that lack the cytoplasmic tail of Env (Murakami and Freed, 2000) . Native HIV-1 replicated in MT4 cells with a rapid peak in p24 antigen detected at 3 days ( Fig. 4A ). Strong cytopathic effects were observed in these cells concomitant with peak virus production. At 7 days post-infection, both the SHIV(MA) and SHIV(MA N1-96) reached high peak p24 levels comparable to those of native HIV-1 (Fig. 4A ). The infections of SHIV(MA) and SHIV(MA N1-96) also exhibited strong cytopathic effects coincident with peak antigen production. This 4-day delay to peak p24 levels in both SHIV(MA) and SHIV(MA N1-96) infections was much shorter than the 4-week culture required of MHIV (Reed et al., 2002) . Furthermore, replication of the SHIV(MA) chimeras did not require the deletion of the Env cytoplasmic tail, as is necessary for replication of MHIV (Reed et al., 2002) or viruses deleted in the globular head of MA (Reil et al., 1998) . Deletion of the cytoplasmic tail slowed the replication of non-chimeric HIV-1, but did not improve the replication of SHIV(MA) or SHIV(MA N1-96) viruses ( Fig. 4A ).
HIV-1 replicated in Jurkat cells with a peak virus production at 7 days post-infection. In contrast, SHIV(MA) and SHIV(MA N1-96) did not replicate in Jurkat cells when infected with a comparable dose of virus ( Fig. 4B ). No cytopathic effects were observed in a 2-week period following Comparison of p24 levels in viral supernatants from transfected 3T3 TXC cells versus the levels p24 in the transfected 3T3 TXC cell lysates. P24 levels were determined by quantitative p24 ELISA. Virus was pelleted through a 20% sucrose cushion prior to analysis. (Akari et al., 2000; Murakami and Freed, 2000) . Deletion of the cytoplasmic tail of Env abolished replication of native HIV-1
in Jurkat cells (Fig. 4B ), as previously reported (Murakami and Freed, 2000) . Our studies further found that the mutation did not rescue replication of SHIV(MA) or SHIV(MA N1-96) (Fig.  4B ). In previous studies (Akari et al., 2000; Murakami and Freed, 2000) , defects in infectivity correlated with decreased levels of Env incorporation onto the virus particles. We therefore examined the compatibility of the SIV MA with the HIV-1 Env in our SHIV(MA) chimeras.
Poor replication in Jurkat correlates with impaired single round infectivity of SHIV(MA) constructs and impaired Env incorporation
To examine the compatibility of the SHIV(MA) chimeric Gag proteins with the HIV-1 Env, we tested these constructs for their ability to infect CD4-expressing HeLa MAGI HIV indicator cell line in a single round of infection. The infectivity of the SHIV(MA) and SHIV(MA N1-96) was 20-to 25-fold lower than native HIV-1 when the viruses were produced with endogenously expressed HIV-1 Env and used to infect HeLa MAGI cells (Fig. 5A ). The deletion of the cytoplasmic tail of Env diminished the infectivity of HIV-1 and did not improve the infectivity of SHIV(MA) or SHIV (MA N1-96) ( Fig. 5A ). HeLa MAGI infectivity assays were performed with a single dose of virus. We also infected CD4+ human osteosarcoma HIV indicator cell line, GHOST, which is induced to express GFP upon infection with HIV-1. We used flow cytometry to count the percentage of target cells infected at varying viral inputs. These experiments showed a linear relationship between dose and infectivity with the native HIV-1 but little infectivity for either SHIV(MA) chimera (Fig. 5B ). The infectivity profile of SHIV(MA) chimeras in both HeLa MAGI and GHOST indicator cells correlated with their poor ability to replicate in Jurkat cells ( Fig. 4B ). Because small sequence differences in HIV-1 MA can affect the efficiency of Env incorporation (Dorfman et al., 1994; Freed and Martin, 1995) , we examined the ability of SHIV(MA) and SHIV(MA N1-96) viruses to incorporate native HIV-1 Env or ΔCT Env. 293T cells transfected with native HIV-1, SHIV(MA) and SHIV(MA N1-96) proviral constructs all expressed similar levels of steady-state Env (Fig. 5C, top) . The smaller molecular weight of the ΔCT constructs carrying the deletion of the cytoplasmic tail was apparent in these blots. Western analysis of virus particles pelleted through 20% sucrose cushions revealed somewhat lower levels of total Env associated with both SHIV(MA) viruses (Fig. 5C, middle) . In particular, the band for gp120 Env was diminished to a greater extent in both the SHIV(MA) and SHIV(MA N1-96) relative to native HIV-1 (Fig. 5C, middle) . Deletion of the cytoplasmic tail increased the levels of the gp120 that pelleted with the SHIV(MA) and SHIV(MA N1-96) virus particles; however, this increase was not associated with increased infectivity (Fig. 5A) . As a control, the levels of p24 CA found in the viral supernatants were not affected by the deletion of the cytoplasmic tail of Env (Fig. 5C, bottom) .
Rescue of infectivity of SHIV(MA) or SHIV(MA N1-96) by VSV-G pseudotyping
To further examine whether compatibility of SIV MA with HIV-1 Env is a major limiting factor in the infectivity of the SHIV(MA) chimeras, we pseudotyped the viruses by cotransfecting the full-length proviral constructs with VSV-G expression plasmid during production in 293T cells. SHIV(MA) or SHIV(MA N1-96) pseudotyped viruses were rescued to the level of VSV-G pseudotyped HIV-1 when tested on HeLa MAGI cells as the target cell (Fig. 6A) . Titration of the VSV-G pseudotyped virus on GHOST indicator cells showed that pseudotyped SHIV(MA) and SHIV(MA N1-96) exhibited a relative infectivity in GHOST cells similar to that of native HIV-1 ( Fig 6B) . Therefore, the low infectivity of the SHIV(MA) chimeras in HeLa MAGI or GHOST indicator cells can be rescued by simple cotransfection of VSV-G during virus production. These data suggest that the low infectivity of SHIV(MA) and SHIV(MA N1-96) is largely attributable to Env compatibility issues.
Selection of variants of SHIV(MA) and SHIV(MA N1-96) with an improved ability to replicate in Jurkat cells
To select for SHIV(MA) variants with higher replicative capacity in Jurkat cells, we pseudotyped the SHIV(MA) and SHIV(MA N1-96) with VSV-G and used the viral supernatants to infect Jurkat cells. This approach allowed a greater number of viruses to infect in the initial round of infection and, as a consequence, enhanced the probability that viruses with favorable mutations were available for selection. Because the VSV-G was provided in trans by transient cotransfection, it enhanced the initial, but not subsequent, rounds of infection. In these cultures, the SHIV(MA N1-96) produced high titers of p24 antigen accompanied by strong cytopathic effects after 21 days in culture (Fig. 7A ). SHIV (MA) construct also produced high levels of p24 after a longer delay, peaking at nearly 31 days post-infection. When viruses from this infection were passaged for a second round in Jurkat cells (designated as p2), the delay in SHIV(MA) replication was much shorter than the original infection (Fig.  7B ). In the second passage, SHIV(MA N1-96)p2 produced a peak titer only 2 days following native HIV-1 and exhibited strong cytopathic effects. In Jurkat cells, SHIV(MA) p2 exhibited a 4-day delay relative to native HIV-1 and also exhibited cytopathic effects. Subsequent passages (passage three and four) of the viruses in Jurkat cells produced SHIV(MA) and SHIV(MA N1-96) isolates that continued to replicate with similar short delays relative to passaged HIV-1 (data not shown). 
Passaged SHIV(MA) chimeras do not replicate in murine 3T3 TXC cells and produce only low levels of virus
Because the SHIV(MA) chimeras assembled in murine cells with higher efficiency when transfected, and a variant of these viruses can replicate efficiently in human T cells, we then tested whether passaged SHIV(MA) would show a greater overall fitness during infection of 3T3 TXC cells. Infection of these cells with the passaged viruses (from passage 4), HIV-1p4 and SHIV(MA N1-96)p4, transiently released low levels p24, without evidence of multi-round replication in these cells (Fig. 7C ). The peak in p24 production occurs 24 to 48 h following infection. The transient peak of p24 production from the SHIV(MA N1-96)p4 is weak, yet only two-fold better than the production from HIV-1p4. To ensure that the p24 released from the cells was not due to carryover of the input virus, an azidothymidine (AZT)-treated control was performed. The low levels of p24 released from the 3T3 TXC cells were sensitive to AZT, indicating that virus measured was produced from newly infected 3T3 TXC cells. Although the SHIV(MA N1-96)p4 virus was able to infect the 3T3 TXC cells, the p24 production was inefficient and unsustained.
Infectivity and Env incorporation on SHIV(MA) chimeras is increased following selection in Jurkat cells
Titering p2-viruses on HeLa MAGI cells revealed that their infectivity was improved relative to unpassaged viruses ( Fig. 8A) displaying an infectivity of 40% of control passaged HIV-1 at highest p24 input. Titration of these passaged viruses on GHOST indicator cells showed that the passaged SHIV(MA) chimeras were improved in titer over unpassaged virus (compared with Figs. 5 and 6 ), yet the passaged HIV-1 was still several-fold more infectious than SHIV(MA)p3 or SHIV(MA N1-96)p3 (Fig. 8B) .
To see if the levels of Env associated with the virus particles changed following passage through Jurkat cells, we compared the pelletable Env from viruses produced in 293T cells to the Jurkat passaged viruses. An anti-gp120 Western blot of sucrosepelleted virus particles harvested from passage 2 shows that the SHIV(MA) chimeric viruses were associated with increased levels of pelletable Env to levels similar to that of native HIV-1 (Fig. 8C, top panel) . In particular, a Western blot with anti-gp41 antibody showed that levels of gp41 in both SHIV(MA) chimeras produced in 293T cells (p0) were lower than native HIV-1, whereas the gp41 levels associated with the SHIV(MA) chimeras were similar to HIV-1 after passage in Jurkat cells (p2) (Fig. 8C, middle panel) . This may indicate that improved packaging of Env or enhanced processing of the gp160 precursor to gp41 and gp120 is responsible for the improved infectivity of the SHIV(MA)p2 and SHIV(MA N1-96)p2. A control immunoblot for p24 shows that the viral pellets from p0 and p2 contained similar levels of capsid antigen (Fig. 8C,  bottom panel) .
To rule out cross-contamination of samples as an explanation for the adaptive changes in Jurkat-passaged SHIV(MA) and SHIV(MA N1-96) and to identify possible compensatory mutations from the original sequence, we isolated RNA from sucrose pelleted viruses and performed direct sequencing of reverse transcriptase mediated PCR products, initially across the entire gag and env open reading frames. Initial sequencing determined that the entire gag from SHIV(MA) or SHIV(MA N1-96) were identical to the input viruses. Therefore, the increased replication of passaged SHIV(MA) chimeras was not attributable to viral cross contamination, a simple reversion to more HIV-like sequences in MA, or a result of second site changes in other regions within gag. Sequencing of SHIV(MA N1-96)p2 and p3 env revealed a three nucleotide deletion resulting in deletion of glutamate 265 (N-terminal to V3) in p3 viruses. There was no evidence of deletion of the cytoplasmic tail that can occur during selection of SIV in human cells (Kodama et al., 1989 ). There were no missense changes in the cytoplasmic tail, suggesting that alterations in the regions of Env that may interact with MA are also not directly responsible for the increased fitness of passaged SHIV(MA N1-96).
Additional sequencing of overlapping PCR products covering the open reading frames from gag through nef, spanning 8700 nucleotides, revealed changes to vpu (stop codons), the ectodomain of env, and nef ( Fig. 9 ). Based on this sequence analysis, it is likely that mutation(s) outside of cytoplasmic tail of Env or Gag is important for the enhanced fitness of the passaged viruses. Alternatively, it is possible that mixed viral populations present in the p3 virus or epigenetic changes are responsible for the improved replication in Jurkat cells. Identification of the key changes responsible for enhanced replication in Jurkat cells will be best approached systematically by creating full-length proviral clones.
Discussion
We have studied an MA-chimeric lentivirus to examine how interactions between MA and host factors can regulate assembly in different cell contexts. In particular, we have examined whether MA-chimeric virus models support greater assembly and replication in murine cells. Previous studies have illustrated that a highly unrelated MA domain from the murine C-type, simple retrovirus, MuLV, can complement the assembly functions of HIV-1 MA in both human and murine cells when inserted in place of the HIV-1 MA sequence (Chen et al., 2001; Reed et al., 2002) . The resulting chimeric virus, which we called MHIV(MA), assembled with a greatly enhanced ability in murine cells but was impaired in its replication. Here, we have found that replacing the HIV-1 MA domain with a highly related sequence from another primate lentivirus, SIV MAC239, also markedly enhanced assembly in murine cells. Replacement of the most highly conserved helical core (amino acids 1-96) of HIV-1 with that from SIV MA was sufficient to improve the efficiency of assembly in murine cells. This further supports the idea that HIV-1 MA plays an important role in limiting the assembly of HIV-1 in murine cells. Unlike the MHIV MA chimeras, we did not observe major changes in the efficiency of Gag processing in the SHIV(MA) chimeras. However, in comparison to our previous studies with the MuLV MA domain, we found that this exchange of lentiviral MA domains resulted in a chimeric virus with greater ability to replicate in human T cell lines, but not in murine 3T3 TXC cells. It is possible that other blocks to efficient replication of SHIV(MA) may exist in these cells.
Although the HIV-1 MA and the SIV MA domain are homologous peptides with similar structures, previous studies show that they differ in their ability to participate in the assembly process. Unlike HIV-1 MA, expression of an isolated SIV MA protein, in the absence of C-terminal Gag sequences, can form virus like particles that can even incorporate the SIV Env (Giddings et al., 1998; Gonzalez et al., 1993) . It is possible that because the SIV MA domain carries additional basic residues near its N-terminus, it may have a higher intrinsic affinity for membranes. Despite these differences, when placed within the context of HIV-1 Gag, the SIV MA did not increase virus production in human 293T cells. Its positive effects on mediating viral assembly were only apparent in murine cells, suggesting that an interaction of the MA domain with the Fig. 8 . Infectivity of the SHIV(MA) chimeras passaged in Jurkat cells is increased on HeLa MAGI and GHOST cells and has greater levels of particle associated Env. (A) Infectivity of passaged SHIV(MA)p2 and SHIV(MA N1-96)p2 on HeLa MAGI indicator cells. Cells were infected with 30 ng of p24 of each virus harvested at peak of replication and stained with X-gal 48 h later. (B) Titration of SHIV(MA)p3, SHIV(MA N1-96)p3, and HIV-1p3 viruses recovered from passage 3 on Jurkat cells were measured for p24 content and used to infect GHOST indicator cells at varying doses. (C) SHIV(MA)p2 and SHIV(MA N1-96)p2 passaged virus incorporate more Env than non-passaged virus produced in 293T cells. Supernatants from non-passaged (p0) or passaged (p2) carrying equivalent levels of p24 were pelleted by ultracentrifugation through 20% sucrose. Viral proteins were separated by SDS-PAGE followed by Western blot analysis using anti gp120 antibody (top), anti-gp41 monoclonal antibody (middle) or anti-HIV-1 antiserum to detect p24 (bottom). cellular environment determines the ability of MA to stimulate Gag assembly.
Heterokaryon fusion experiments suggest that the block to HIV-1 assembly may be caused by the absence of a factor that is required for HIV-1 assembly (Bieniasz and Cullen, 2000; Mariani et al., 2001) . Our studies of SHIV(MA) chimeras further support the hypothesis that this putative missing factor(s) may interact with MA. It has recently been found that the MA domain of Gag can interact with the delta subunit of the adapter protein complex 3 (AP-3δ), and that this interaction is important for assembly of HIV-1 (Dong et al., 2005) . It will therefore be interesting to determine what role AP-3, or other cellular factors, play in regulating the location and efficiency of assembly of SIV or SHIV(MA) chimeras. It is possible that sequence differences in MA that enhance assembly may improve the ability of the chimeric Gag protein to interact with a putative murine cofactor of assembly. The high sequence similarity of SIV MA and HIV-1 MA may allow us to map the structural features responsible for enhanced assembly in murine cells. An approach that investigates the ability of proteins to bind differentially to a SHIV(MA) Gag, but not HIV-1 Gag, may identify key factors that facilitate assembly in murine cells.
To further evaluate the promise of SHIV(MA) chimeras in developing a mouse model, we tested the compatibility of the SIV MA during viral replication. The MA domain of HIV-1 is intimately involved in recruiting the Env glycoprotein into the virus particle through an interaction with the Env cytoplasmic tail (Freed and Martin, 1996; Ono et al., 1997) . We found that the SHIV(MA) chimeric viruses were replication competent in highly permissive MT4 cells, but were less efficient at replication in Jurkat cells. Despite the high sequence similarity of SIV MA and HIV-1 MA, the SIV MA was poorly compatible with HIV-1 Env. Although some Env was incorporated into these SHIV(MA) particles, it was less efficient at infection of Jurkat, HeLa MAGI, or GHOST indicator cells. We noticed in the two SHIV(MA) viruses that relatively little pelletable Env was found in the processed gp120 form. This defect may in part be responsible for the decreased infectivity of both SHIV(MA) chimeras on HeLa MAGI cells and Jurkat cells. Complementing these viruses with VSV-G rescued their infectivity. While deletion of cytoplasmic tail appeared to improve the ratio of gp120 to unprocessed precursor on SHIV(MA) chimeras, it did not result in an increase in infectivity. This phenotype distinguishes the SHIV(MA) chimeras from the MHIV(MA) (Reed et al., 2002) and ΔMA mutants (Reil et al., 1998) , which both require the ΔCT Env mutation to replicate. In comparison to these other MA-mutant/chimeras, the Env incorporation defect in SHIV(MA) was much less severe.
Cell-type-dependent replication has been observed for viruses with deletions in the Env cytoplasmic tail and has been proposed as evidence for the importance of cellspecific factors in modulating Env incorporation (Akari et al., 2000; Murakami and Freed, 2000) . The ability of unpassaged SHIV(MA) viruses to infect MT4 cells, but not Jurkat cells, suggests that host factors regulate the interaction between MA and Env. Selection of these viruses for high-level replication in Jurkat cells improved the levels of Env on virus particles and their infectivity. Unexpectedly, our sequencing of the passaged viruses indicated that sequences outside of Gag or the cytoplasmic tail of Env may influence the compatibility of MA with replication in Jurkat cells. Alternatively, complex mixtures of adaptive changes in the viruses, or epigenetic alterations during propagation in T cells, could be responsible for the adaptive phenotype. It will be interesting to determine what genetic loci in HIV may modulate the compatibility of MA and Env. These studies will be facilitated by the creation of full-length clones of the passaged viruses.
Additional selection of SHIV(MA) chimeras in murine cells may identify HIV-1 variants with improved assembly and improved infectivity in murine cells. If a variant can be found to replicate in multiple rounds in murine cells, it may provide a useful model for the infection of transgenic mice. The continued study of these chimeras and their ability to Fig. 9 . Genomic location of sequence changes identified by sequencing of PCR products from HIV-1p3 and SHIV(MA N1-96)p3. The nomenclature for the mutations is as follows: the single letter abbreviation for the native amino acid, followed by its position within the protein, followed by the mutated amino acid. The gene in which the mutation occurs is labeled below the mutation. No conservative changes were identified. Partial mutations with mixtures of two bases are indicated with an asterisk. The region covered by RT-PCR mediated sequencing is indicated with the black bar on the bottom. replicate in various cell environments may help to identify the host factors that regulate assembly, envelope incorporation and viral infectivity.
Materials and methods
Plasmids, cell lines, and transfections
Chimeric proviral Gag constructs were produced by modification of the HIV-1 proviral construct, pNL4-3 (Adachi et al., 1986) inserting sequences from SIV MAC239 molecular clone (Kestler et al., 1990; Regier and Desrosiers, 1990) . PCR based mutagenesis was employed to create SHIV(MA) and SHIV(MA N1-96). The nucleotide sequence of the 5′ HIV-SIV junction was 5′-CGGAGGCTAGAAGGAGAGAGatgggcgtgagaaactccgtc-3′ where uppercase letters represent HIV-1 derived sequences and lowercase letters represent SIV derived sequences. The 3′ junction for SHIV(MA) is represented by the following oligo: 5′-tagcggcagaggaggaaattacCCTATAGTG-CAGAACCTCCAGG-3′ and the 3′ junction for SHIV(MA N1-96) is represented by the following oligo: 5′-tgcattcacgca-gaagagaaagtgaaacacACCAAGGAAGCCTTAGATAAGATA-GAGGAA-3′. Chimeric gag sequences were inserted into pNL4-3 using unique BssHII and SpeI sites. Mutant proviral clones with a deletion of the C-terminal 147 amino acids referred to as ΔCT were constructed with the following mutagenic oligo, 5′-GTACTTTCTATAGTGAATAGAGT-TAGGtaGtaATATTCACCATTATCGTTTCAGACC-3′, where the lowercase letters represent the mutations that insert a stop codon into the env reading frame of molecular clone of HIV-1, pNL4-3. MHIV(MA) studied in Chen et al. (2001) were modified to encode an HIV-1 protease cleavage site that replicates the native HIV-1 MA-CA junction between the MLV MA and HIV-1 CA, designated MHIV(MA)v2. Another construct, MHIV(MA12)v2, carries an HIV-1 MA-CA junctional sequence between MLV MA and MLV p12. Nucleotide sequences for the novel junctions created for each indicated constructs are as follows (lowercase are MLV derived and uppercase are HIV-derived sequences). In MHIV(MA)v2, sequence of the MA-CA junction is as follows: 5′-tcgaccccgcctcgatccAGCCAAAATTACCCTATAGTGCAG-3′. In MHIV(MA12)v2, the following sequence inserts HIV-1 protease cleavage site between the MLV p15 and p12 sequences: 5′-tcgaccccgcctcgatccCAAAATTACCCTA-TAGTGCAGccttctctaggcgccaaacc-3′. All PCR generated mutations were confirmed by sequencing of the entire amplified regions.
Human embryonic kidney cells expressing T antigen, 293T, and NIH 3T3 cells expressing human CD4, CXCR4, and cyclin T1 were previously described (Chen et al., 2001) . Human 293T cells were transfected with standard calcium phosphate methods (Ausubel et al., 2003) , and 3T3 TXC cells were transfected with Lipofectamine 2000 (Invitrogen), according to manufacturers instructions. HeLa MAGI indicator cells from Michael Emerman (Kimpton and Emerman, 1992) and CD4 + GFP-expressing human osteosarcoma cell line, GHOST, from Vineet KewalRamani and Dr. Dan Littman (Morner et al., 1999) , were obtained through the AIDS Research and Reference Reagent Program (ARRRP).
Western blots, ELISA
Cell lysates were prepared by lysis of transfected cells in 1% triton lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA (TNE), 1% Triton X-100, and protease inhibitor cocktail). Viral supernatants were pelleted by ultracentrifugation for 2 h at 36,000 rpm in SW50.1 rotor through a 20% sucrose cushion. Pelleted viruses were resuspended in 1% Triton lysis buffer and proteins separated by LDS PAGE, using 4-12% gradient NuPAGE Gels (Invitrogen). Polyclonal human anti-HIV-1 patient immune globulin, obtained from Alfred Prince through the ARRRP, was diluted to 1:5000 for Western analyses. Polyclonal sheep anti-HIV-1 Env, obtained from Michael Phelan through the ARRRP, was diluted 1:2500 for Western analyses. Western blots were developed with horseradish peroxidase coupled secondary antibodies followed by Enhanced Chemiluminescence Assay (Amersham). Luminescence based ELISA assay using commercial antibodies (International Enzymes) has been previously described and provides a highly quantitative assay with large dynamic range (McKeating et al., 1991; Moore et al., 1990) .
Infectivity assays, HeLa MAGI, and luciferase assays
Infectivity of virus was assessed by titering viruses on CD4 + HeLa MAGI cells (Kimpton and Emerman, 1992) or GHOST cells (Morner et al., 1999) . Cells were exposed to indicated concentrations of virus in the presence of 4 μg/ml of polybrene (Sigma) and washed 24 h post-infection. At 48 h post-infection, cells were fixed and stained for beta-galactosidase activity in situ for HeLa MAGI assays. The number of infectious blue foci per high-powered field was counted and averaged across 6 random fields. For GHOST cell analysis, infected cells were trypsinized, fixed in 4% paraformaldehyde, and GFP-expressing infected cells were enumerated by flow cytometry. Pseudotyped proviral constructs were produced by transient transfection of 293T cells, cotransfecting proviral DNA with an equal amount of VSV-G expression vector, pMD-G (Ory et al., 1996) . Viral supernatants were harvested at 48 h posttransfection, clarified by centrifugation (400×g for 5 min) and 0.45-μm filtration and used to infect human HeLa MAGI cells or GHOST cells.
Viral growth assay
Viral supernatants were produced by transient transfection of 293T cells and stored at −80°C prior to infection. Infection of MT4 cells or Jurkat cells was performed with viral supernatants containing the indicated amounts of p24. At 24 h post-infection, cells were washed twice with growth media to remove input viral antigens, and viral supernatants were subsequently collected at 2-day intervals when cells were split at a constant 1:3 dilution.
